DA Davidson maintains Phreesia at Buy, raises price target to $15 from $13
DA Davidson reaffirmed its Buy rating for Phreesia and increased its price target to $15 from $13, citing a 22.3% upside from the Nov 18 close of $12.26.
How this was made

The 30-second read
Why it matters
The price‑target increase signals a shift in analyst sentiment, which may attract short‑term buying.
Market read
Analyst upgrade could trigger modest price movement in Phreesia.
What to watch
Potential dilution from future financing rounds not addressed.
Background
Phreesia is a cloud‑based patient intake platform; analyst coverage is limited.
Market effects
May lift sentiment in the health‑tech sector.
Limited to US small‑cap market.
Minimal.
Counterpoint
Target raise could be premature if upcoming earnings miss expectations.
Key entities
- Analyst FirmDA Davidson
Raised Phreesia price target to $15.




